Mammary Cell News 10.44 November 8, 2018 | |
| |
TOP STORYCancer Cells Exploit an Orphan RNA to Drive Metastatic Progression Scientists performed a systematic search to identify breast-cancer-specific small noncoding RNAs, which they have collectively termed orphan noncoding RNAs (oncRNAs). They subsequently discovered that one of these oncRNAs, which originates from the 3′ end of TERC, acts as a regulator of gene expression and is a robust promoter of breast cancer metastasis. [Nat Med] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers identified a tight junction (TJ)-based signalosome, which controls AKT signaling and epithelial-mesenchymal transition in breast cancer. The coxsackie- and adenovirus receptor (CXADR), a TJ protein with an essential yet uncharacterized role in organogenesis and tissue homeostasis, was identified as a key component of the signalosome. [Cancer Res] Abstract | Press Release Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes Investigators identified a keratin 6a-expressing precancerous stem cell subset and a more differentiated whey acidic protein-positive cell subset in mammary precancerous lesions initiated by the Wnt1 oncogene. Both cell subsets rapidly progressed to cancer upon introduction of constitutively active versions of either HRAS or BRAF. [Cancer Res] Abstract Acetylation of ACAP4 Regulates CCL18-Elicited Breast Cancer Cell Migration and Invasion Scientists showed that ARF6 GTPase-activating protein ACAP4 regulates CCL18-elicited breast cancer cell migration via the acetyltransferase PCAF-mediated acetylation. CCL18 stimulation elicited breast cancer cell migration and invasion via PCAF-dependent acetylation. [J Mol Cell Biol] Abstract An imidazole moiety was linked to the skeleton of tanshinone-IIA (Tan-IIA) to enhance its antitumor activity. A series of Tan-IIA-based analogs TA01-TA12 were synthesized, and their inhibitory activities against the migration and invasion of MDA-MB-231 cells were investigated. All compounds, particularly TA12, markedly inhibited the proliferation, migration and invasion of MDA-MB-231cells. [J Med Chem] Abstract Statins Attenuate Outgrowth of Breast Cancer Metastases The authors examined statin efficacy against two breast cancer cell lines in models of breast cancer metastasis: a 2D in vitro co-culture model of breast cancer cell interaction with the liver, a 3D ex vivo microphysiological system model of breast cancer metastasis, and two independent mouse models of spontaneous breast cancer metastasis to the lung and liver, respectively. [Br J Cancer] Abstract Using two models of breast cancer, T47D cells with blocked synthesis of sulfatide and MDA-MB-231 cells with neosynthesis of this glycosphingolipid, scientists showed that high sulfatide levels resulted in increased sensitivity of cancer cells to apoptosis induced by hypoxia and doxorubicin in vitro, and decreased their tumorigenicity after transplantation into athymic nu/nu mice. [Breast Cancer Res] Full Article The antiproliferative and antitumor effects of dronedarone, an FDA-approved anti-arrhythmic drug which has been shown to antagonize THRα1, was evaluated in breast cancer cell lines in vitro and in vivo. [Sci Rep] Full Article The putative mammary stem cell (MaSC) fraction was recovered in the CD49fhighCD24pos sub-population which were shown to form mammospheres in vitro. These cells differentially expressed CD10, KRT14 and KRT7, suggesting the existence of several putative MaSC sub-fractions. [Sci Rep] Full Article Researchers evaluated efficacy and assessed concentration-effect relationships of AR-C155858 (a selective and potent MCT1 inhibitor) in murine 4T1 breast cancer cells and in the 4T1 tumor xenograft model. [AAPS J] Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSRegulation of RAS signaling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach in breast cancer therapy. Scientists summarize the recent knowledge about the clinical value of RAS prenylation pharmacological inhibitors in breast cancer treatment. [J Cell Biochem] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSOncoSec Doses First Patient in KEYNOTE-890 Phase II Clinical Trial OncoSec Medical Incorporated announced that the first patient has been treated in KEYNOTE-890, a Phase II clinical trial for the treatment of late-stage triple negative breast cancer with TAVO™ in combination with Merck’s KEYTRUDA®. [OncoSec Medical Incorporated] Press Release CytoDyn Inc. announced that it has submitted an investigational new drug (IND) application to the FDA to conduct a Phase Ib/II clinical trial with PRO 140 as a therapy for patients with metastatic triple-negative breast cancer. [CytoDyn Inc.] Press Release | |
| |
POLICY NEWSScientists Struggle with Confusing Journal Guidelines Globally, more than two-thirds of researchers find it difficult to prepare manuscripts and to respond to peer-review comments, finds a survey of nearly 7,000 researchers from over 100 countries. [Nature News] Editorial Open-Access Plan Draws Online Protest Hundreds of scientists are pushing back against Plan S, a plan to crack down on scholarly journals’ paywalls, launched 2 months ago by 11 national research funders in Europe. In an open letter published on 5 November, about 800 signatories say they support open access-making papers available free to all readers online-but condemn Plan S as “too risky for science.” [ScienceInsider] Editorial Europe’s Researchers Benefit From Reduced Bureaucracy The European Union has made good on its promise to reduce the amount of red tape that scientists must wade through when applying for grants from its flagship funding program, according to a report released by the European Court of Auditors. [Nature News] Editorial
| |
EVENTSNEW Gordon Research Conference: Heterogeneity in Mammary Gland Development and Breast Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Scientist – Cancer (Université de Bordeaux/Inserm/CNRS) Senior Coordinator, Clinical Studies – Breast Medical Oncology (MD Anderson Cancer Center) Research Assistant – Breast Medical Oncology (MD Anderson Cancer Center) Faculty Position – Cancer Pathobiology (University of Alabama at Birmingham) Researcher Positions – Cancer (University of Bergen) Research Fellow – Immunology (King’s College London) Postdoctoral Position – Novel Cancer Gene and Therapy (University of Notre Dame) Research Associate – Immunology (King’s College London) Research Associate – CAR T-Cell Immunotherapy (King’s College London) Postdoctoral Fellowship – Epigenetics and RNA Biology (Umeå University) Assistant/Associate/Professor – Department of Cancer Biology (University of Cincinnati) Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|